CD20 +

About

Biomarker Type: Protein expression

Present: True

Marker: CD20

Unit: status

Equality: =

Value: Positive


Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organization(s) Biomarker(s) Cancer type Therapy(ies)
FDA (1) HC (1) CD20 + Non-Hodgkin Lymphoma Rituximab
FDA (1) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Prednisolone, Rituximab, Vincristine
FDA (1) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine
FDA (1) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Fludarabine, Mitoxantrone, Rituximab
FDA (2) CD20 + Non-Hodgkin Lymphoma Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
FDA (1) HC (1) CD20 + Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
FDA (1) CD20 + Burkitt Lymphoma Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
FDA (1) CD20 + Mature B-Cell Neoplasms Cyclophosphamide, Doxorubicin, Prednisone, Rituximab, Vincristine
FDA (1) CD20 + Chronic Lymphocytic Leukemia Cyclophosphamide, Fludarabine, Rituximab
HC (1) CD20 + Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin, Prednisolone, Rituximab, Vincristine
HC (1) CD20 + Follicular Lymphoma Cyclophosphamide, Prednisolone, Rituximab, Vincristine
HC (1) CD20 + Follicular Lymphoma Rituximab